---
title: "JINGXIN: Net profit in the first half of 2025 is 388 million yuan, a year-on-year decrease of 3.54%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/254621949.md"
description: "JINGXIN announced that in the first half of 2025, operating revenue was 2.017 billion yuan, a year-on-year decrease of 6.20%. Net profit was 388 million yuan, a year-on-year decrease of 3.54%. The company plans not to distribute cash dividends, not to issue bonus shares, and not to convert reserves into share capital"
datetime: "2025-08-26T11:57:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/254621949.md)
  - [en](https://longbridge.com/en/news/254621949.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/254621949.md)
---

# JINGXIN: Net profit in the first half of 2025 is 388 million yuan, a year-on-year decrease of 3.54%

JINGXIN announced that in the first half of 2025, the operating income was 2.017 billion yuan, a year-on-year decrease of 6.20%. The net profit was 388 million yuan, a year-on-year decrease of 3.54%. The company plans not to distribute cash dividends, not to issue bonus shares, and not to convert reserves into share capital

### Related Stocks

- [002020.CN](https://longbridge.com/en/quote/002020.CN.md)

## Related News & Research

- [European Wealth Management Stocks For Investors Rethinking AI Heavy Portfolios](https://longbridge.com/en/news/296249753.md)
- [Nasdaq Futures Plunge as Rising Bond Yields Drive Chip Selloff](https://longbridge.com/en/news/296216952.md)
- [EXPLAINER-Why a super El Niño leaves tropical commodities acutely exposed](https://longbridge.com/en/news/296197492.md)
- ['Worrisome': AI is driving a looming market correction, central bank economists warn](https://longbridge.com/en/news/296226776.md)
- [CSPC Innovation Pharmaceutical: Biopharma licensing and product launches drove record revenue and profit growth](https://longbridge.com/en/news/296129143.md)